Coronavirus disease 19 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), can be associated with changes in platelet count [1, 2]. Thrombocytopenia has been reported in up to 40% of COVID-19 infections [3-5] and is an important marker for morbidity and mortality [1, 2, 5]. Hence, monitoring of platelet counts is important in diagnosis and treatment of COVID-19 patients. Thrombocytopenia can be a result of the COVID-19 infection itself (septicaemia), diffuse intravascular coagulation (DIC), medication or a COVID-19-associated immune thrombocytopenic purpura (ITP) [6]. A rare and often missed alternative explanation of thrombocytopenia is pseudothrombocytopenia [7]. Pseudothrombocytopenia or spurious thrombocytopenia is an in vitro phenomenon of platelet agglutination caused by an anticoagulant, usually ethylenediaminetetraacetic acid (EDTA), resulting in a falsely lowered automated platelet count [8]. The mechanism of pseudothrombocytopenia is not clearly defined, but it is suggested to be an immunologically mediated phenomenon of platelet clumping due to the formation of immune complexes between naturally occurring autoantibodies and cryptic epitopes of the glycoprotein IIb/IIIa complex on the platelet membrane that are exposed by the EDTA anticoagulant used for routine blood sample collections [9]. This phenomenon has been previously reported to be associated with autoimmune diseases and infections [10], such as hepatitis A [11], mononucleosis [12] and Plasmodium falciparum malaria [13]. It has a reported incidence between 0.03% and 0.27% among the general population [14]. Here, we report the first patient with pseudothrombocytopenia related to COVID-19 infection and its natural course. [...]